Evofem Biosciences, Inc. filed a Form 8-K on November 18, 2026, disclosing that a 1-for-1,500 reverse stock split of its common stock became effective at the open of trading on the OTCID on that date.

Key Highlights

  • Split ratio: The board selected a 1-for-1,500 ratio, within the shareholder-approved range of not less than 1-for-500 and not more than 1-for-1,500.
  • Effective date: The reverse stock split became effective upon the open of trading on the OTCID on November 18, 2026, following a Certificate of Correction filed November 17, 2026.
  • Shareholder approval: Shareholders approved the amendment at the Annual Meeting held on November 26, 2025.
  • Fractional share price: Fractional shares are to be cashed out at $0.0043, the closing trading price of the common stock on the trading day immediately preceding the effective time.
  • New CUSIP: The new CUSIP number for the common stock following the reverse stock split is 30048L401.
  • Trading symbols: The common stock trades on the OTCID under the symbol "EVFMD" and, after twenty business days, will continue under the symbol "EVFM."
  • Authorized shares: The company's total authorized common stock remains unchanged.

Evofem Biosciences Implements 1-for-1,500 Reverse Split, Corrects Effective Date to November 18, 2026

According to the filing, Evofem Biosciences, Inc. reported that it effected a one-time reverse stock split of its common stock at a ratio of 1-for-1,500. The company disclosed that every 1,500 shares of issued and outstanding common stock, as well as shares held in treasury, were automatically converted into one share of common stock at the effective time, with no change in the par value per share.

The filing states that the Certificate of Amendment to the Amended and Restated Certificate of Incorporation was originally filed with the Secretary of State of Delaware on November 5, 2026, with the intent of effectuating the reverse stock split. However, the company subsequently filed a Certificate of Correction on November 17, 2026, to change the effective time from November 5, 2026 to November 18, 2026. As a result, the reverse stock split became effective upon the open of trading on the OTCID on November 18, 2026. The common stock is listed on the OTCID; the filing does not assign a standard exchange designation in the registered-securities table, listing "None" under Section 12(b).

The filing further discloses that proportionate adjustments will be made to the per share exercise price and the number of shares issuable upon exercise of all outstanding stock options, stock appreciation rights, convertible notes, and warrants, as well as shares issuable upon the vesting of restricted stock awards and shares reserved under the company's equity incentive compensation plans. The filing notes that forward-looking statements in the current report involve known and unknown risks and uncertainties, and that actual results could differ materially, as described in the company's cautionary language.

What Was Disclosed

Evofem Biosciences disclosed the implementation of a 1-for-1,500 reverse stock split effective November 18, 2026, including the corrected effective date, the new CUSIP number 30048L401, the temporary trading symbol "EVFMD," and the fractional share cash-out price of $0.0043.